Publikationen von Vijay Kumar Ulaganathan

Ulaganathan, V. K.: TraPS-VarI: Identifying genetic variants altering phosphotyrosine based signalling motifs. Scientific Reports 10 (1), 8453 (2020)

Kogan, D.; Grabner, A.; Yanucil, C.; Faul, C.; Ulaganathan, V. K.: STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion. Journal of Clinical Investigation 128 (5), S. 1867 - 1872 (2018)

Ulaganathan, V. K.; Ullrich, A.: Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants. Molecular & Cellular Oncology 3 (3), e1145176 (2016)

Ulaganathan, V. K.; Sperl, B.; Rapp, U. R.; Ullrich, A.: Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. NATURE 528 (7583), S. 570 - 574 (2015)

Lytton, S. D.; Antiga, E.; Pfeiffer, S.; Matthias, T.; Szaflarska-Poplawska, A.; Ulaganathan, V. K.; Placek, W.; Fabbri, P.; Hall, R.; Caproni, M.: Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease - Dermatitis herpetiformis. CLINICA CHIMICA ACTA 415, S. 346 - 349 (2013)

Ulaganathan, V. K.; Sperl, B.; Mayr, T.; Hornberger, R.; Rapp, U. R.; Ullrich, A.: A gain of function by the cancer-associated FGFR4 c. 1162G>A (p. Gly388Arg) variant. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 446, S. S107 - S108. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)